APGE · As filed with the SEC
Apogee Therapeutics cash flow statement, by quarter
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | — | (74,111,000) | — | — |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||
| Depreciation expense | — | 408,000 | — | — |
| Equity-based compensation expense | — | 17,155,000 | — | — |
| Amortization of discounts on marketable securities | — | (1,549,000) | — | — |
| Non-cash lease expense | — | 980,000 | — | — |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | — | (2,490,000) | — | — |
| Other non-current assets | — | 155,000 | — | — |
| Accounts payable | — | 16,000 | — | — |
| Operating lease liability | — | (802,000) | — | — |
| Accrued expenses | — | 4,668,000 | — | — |
| Net cash used in operating activities | — | (55,570,000) | — | — |
| Cash flows from investing activities: | ||||
| Purchases of marketable securities | — | (183,244,000) | — | — |
| Maturities and sales of marketable securities | — | 147,895,000 | — | — |
| Net cash (used in) provided by investing activities | — | (35,349,000) | — | — |
| Cash flows from financing activities: | ||||
| Proceeds from issuance of common stock, net of issuance costs | — | 378,169,000 | — | — |
| Proceeds from issuance of common stock under the ATM Facility, net of issuance costs | — | 28,934,000 | — | — |
| Proceeds from exercise of options | — | 4,064,000 | — | — |
| Net cash provided by financing activities | — | 411,167,000 | — | — |
| Decrease in cash, cash equivalents and restricted cash | — | 320,248,000 | — | — |
| Cash, cash equivalents and restricted cash, beginning of period | 451,797,000 | 131,549,000 | 107,914,000 | 124,486,000 |
| Cash, cash equivalents and restricted cash, end of period | 105,571,000 | 451,797,000 | 131,549,000 | 107,914,000 |
| Supplemental disclosures of non-cash activities: | ||||
| Unpaid financing cost in accrued liability | — | 728,000 | — | — |
| Issuance of common stock upon exercise of stock options for which proceeds had not yet been received | — | 256,000 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.